Crescent Biopharma
CBIO
69 hedge funds and large institutions have $111M invested in Crescent Biopharma in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 10 closing their positions.
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
75% more call options, than puts
Call options by funds: $3.4M | Put options by funds: $1.95M
33% more capital invested
Capital invested by funds: $82.8M → $111M (+$27.7M)
19% more funds holding
Funds holding: 58 → 69 (+11)
0.03% more ownership
Funds ownership: 0.55% → 0.57% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.12M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.32M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.02M |
| 4 |
Jane Street
New York
|
+$694K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$643K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$2.78M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$629K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$546K |
| 4 |
Two Sigma Advisers
New York
|
-$407K |
| 5 |
AO
Advisor OS
Chicago,
Illinois
|
-$238K |
CBIO Hedge Fund Activity: Q1 2024 in Review
69 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2024, worth a combined $111M — up 33% from $82.8M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CBIO positions and 10 closed out — a net gain of 11 holders — while 23 added to existing stakes and 9 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.12M. The largest seller was NEA Management Company, cutting an estimated $2.78M.
- 69 institutional investors held Crescent Biopharma (CBIO) as of Q1 2024, up from 58 in Q4 2023.
- Funds reported $111M of Crescent Biopharma stock for Q1 2024, up 33% quarter-over-quarter.
- 21 funds opened new Crescent Biopharma positions in Q1 2024 and 10 closed out, a net change of +11 holders.
- The largest Crescent Biopharma buyer in Q1 2024 was Millennium Management, an estimated $2.12M added.
- The largest Crescent Biopharma seller in Q1 2024 was NEA Management Company, an estimated $2.78M sold.
Based on aggregated 13F filings for Q1 2024.